78 related articles for article (PubMed ID: 9704030)
1. Modulation of androgen and progesterone receptors by phytochemicals in breast cancer cell lines.
Rosenberg RS; Grass L; Jenkins DJ; Kendall CW; Diamandis EP
Biochem Biophys Res Commun; 1998 Jul; 248(3):935-9. PubMed ID: 9704030
[TBL] [Abstract][Full Text] [Related]
2. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
3. Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells.
Attardi BJ; Burgenson J; Hild SA; Reel JR
Mol Cell Endocrinol; 2004 Jul; 222(1-2):121-32. PubMed ID: 15249132
[TBL] [Abstract][Full Text] [Related]
4. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
5. Antiandrogenic activity of the phytoestrogens naringenin, 6-(1,1-dimethylallyl)naringenin and 8-prenylnaringenin.
Zierau O; Morrissey C; Watson RW; Schwab P; Kolba S; Metz P; Vollmer G
Planta Med; 2003 Sep; 69(9):856-8. PubMed ID: 14598215
[TBL] [Abstract][Full Text] [Related]
6. Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines.
Paliouras M; Diamandis EP
Breast Cancer Res Treat; 2007 Mar; 102(1):7-18. PubMed ID: 16897430
[TBL] [Abstract][Full Text] [Related]
7. The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines.
Majumdar S; Diamandis EP
Br J Cancer; 1999 Mar; 79(9-10):1594-602. PubMed ID: 10188912
[TBL] [Abstract][Full Text] [Related]
8. Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer.
Zarghami N; Grass L; Diamandis EP
Br J Cancer; 1997; 75(4):579-88. PubMed ID: 9052414
[TBL] [Abstract][Full Text] [Related]
9. Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis.
Afonja O; Juste D; Das S; Matsuhashi S; Samuels HH
Oncogene; 2004 Oct; 23(49):8135-45. PubMed ID: 15361828
[TBL] [Abstract][Full Text] [Related]
10. Definition of the cellular mechanisms which distinguish between hormone and antihormone activated steroid receptors.
McDonnell DP; Clemm DL; Imhof MO
Semin Cancer Biol; 1994 Oct; 5(5):327-36. PubMed ID: 7849261
[TBL] [Abstract][Full Text] [Related]
11. Steroid hormone regulation of the human kallikrein 10 (KLK10) gene in cancer cell lines and functional characterization of the KLK10 gene promoter.
Luo LY; Grass L; Diamandis EP
Clin Chim Acta; 2003 Nov; 337(1-2):115-26. PubMed ID: 14568187
[TBL] [Abstract][Full Text] [Related]
12. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
14. The growth inhibitory activity of the Cimicifuga racemosa extract Ze 450 is mediated through estrogen and progesterone receptors-independent pathways.
Garita-Hernandez M; Calzado MA; Caballero FJ; Macho A; Muñoz E; Meier B; Brattström A; Fiebich BL; Appel K
Planta Med; 2006 Mar; 72(4):317-23. PubMed ID: 16557472
[TBL] [Abstract][Full Text] [Related]
15. Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol.
Chen F; Knecht K; Leu C; Rutledge SJ; Scafonas A; Gambone C; Vogel R; Zhang H; Kasparcova V; Bai C; Harada S; Schmidt A; Reszka A; Freedman L
J Steroid Biochem Mol Biol; 2004 Aug; 91(4-5):247-57. PubMed ID: 15336702
[TBL] [Abstract][Full Text] [Related]
16. Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia.
Banham AH; Boddy J; Launchbury R; Han C; Turley H; Malone PR; Harris AL; Fox SB
Prostate; 2007 Jul; 67(10):1091-8. PubMed ID: 17477366
[TBL] [Abstract][Full Text] [Related]
17. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
Hodgson MC; Astapova I; Hollenberg AN; Balk SP
Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
[TBL] [Abstract][Full Text] [Related]
18. Sensitive in vitro test systems to determine androgenic/antiandrogenic activity.
Guth SE; Böhm S; Mussler BH; Eisenbrand G
Mol Nutr Food Res; 2004 Sep; 48(4):282-91. PubMed ID: 15497179
[TBL] [Abstract][Full Text] [Related]
19. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
Sadar MD; Gleave ME
Cancer Res; 2000 Oct; 60(20):5825-31. PubMed ID: 11059779
[TBL] [Abstract][Full Text] [Related]
20. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
